- Home
- TURN vs RADX Comparison
TURN vs RADX Comparison
Compare TURN & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- RADX
- Stock Information
- Founded
- TURN 1981
- RADX 2021
- Country
- TURN United States
- RADX Australia
- Employees
- TURN N/A
- RADX N/A
- Industry
- TURN Finance/Investors Services
- RADX
- Sector
- TURN Finance
- RADX
- Exchange
- TURN Nasdaq
- RADX NYSE
- Market Cap
- TURN 39.9M
- RADX 32.5M
- IPO Year
- TURN N/A
- RADX N/A
- Fundamental
- Price
- TURN $4.12
- RADX $4.20
- Analyst Decision
- TURN
- RADX Strong Buy
- Analyst Count
- TURN 0
- RADX 2
- Target Price
- TURN N/A
- RADX $13.50
- AVG Volume (30 Days)
- TURN 24.8K
- RADX 18.6K
- Earning Date
- TURN 01-01-0001
- RADX 02-26-2025
- Dividend Yield
- TURN N/A
- RADX N/A
- EPS Growth
- TURN N/A
- RADX N/A
- EPS
- TURN N/A
- RADX N/A
- Revenue
- TURN $194,813.00
- RADX $204,609.00
- Revenue This Year
- TURN N/A
- RADX N/A
- Revenue Next Year
- TURN N/A
- RADX N/A
- P/E Ratio
- TURN N/A
- RADX N/A
- Revenue Growth
- TURN 254.25
- RADX N/A
- 52 Week Low
- TURN $3.12
- RADX $3.50
- 52 Week High
- TURN $4.25
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- TURN 64.75
- RADX N/A
- Support Level
- TURN $3.94
- RADX N/A
- Resistance Level
- TURN $4.16
- RADX N/A
- Average True Range (ATR)
- TURN 0.07
- RADX 0.00
- MACD
- TURN 0.02
- RADX 0.00
- Stochastic Oscillator
- TURN 82.61
- RADX 0.00
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.